Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Regenxbio Inc. manages a portfolio with 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 9 distinct examiners and 7 distinct art units, indicating a high degree of diversification in the examination process. The involvement of 7 distinct art units suggests that the company's biotechnology innovations span a wide range of specialized classifications, requiring the company to navigate numerous different examination groups simultaneously.
BOESEN, AGNIESZKA is the busiest examiner, currently handling 1 pending office action. Since there are 9 distinct examiners for 9 total actions, each examiner is responsible for exactly one matter. This one-to-one ratio between examiners and pending actions means that no single examiner has a dominant influence over the portfolio's direction. The high count of 7 distinct art units relative to the 9 pending office actions highlights the technical breadth of the company's filings, as almost every pending action is being evaluated under a different set of art unit guidelines.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 5 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.5% | +21.8% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 36.1% | +75.9% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 22.2% | +35.7% |
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
| YU, TIAN NMN | 1 | 55.1% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 50d overdue |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | — |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | — |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257820 | METHOD OF PRODUCING A RECOMBINANT VIRUS PARTICLE | LY, KRISTINA ELISABETH | 60d overdue |
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 50d overdue |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 18777913 | ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTION | BOESEN, AGNIESZKA | — |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | — |
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | — |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1633 | 1 |
| 1636 | 1 |
| 1671 | 1 |
| 1634 | 1 |
| 1656 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18777913 | ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTION | BOESEN, AGNIESZKA | — | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | 1633 | §103Other | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18257820 | METHOD OF PRODUCING A RECOMBINANT VIRUS PARTICLE | LY, KRISTINA ELISABETH | 1671 | §103Other | Final Rejection | 60d overdue | Pending | Jun 15, 2023 |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103§112 | Non-Final OA | 33d | Pending | Apr 26, 2023 |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | 1656 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2021 |
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 1681 | §103§112 | Final Rejection | 50d overdue | Pending | Apr 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial